Altered expression of TLR homolog RP105 on monocytes hypersensitive to LPS in patients with primary biliary cirrhosis

• DOI: 10.1016/j.jhep.2007.03.012
• Publication Date: 2007-04-06T15:55:17Z
• Authors: Yutaka Honda; Satoshi Yamagiwa; Yasunobu Matsuda; Masaaki Takamura; Takafumi Ichida; Yutaka Aoyagi
• Keywords: Lipopolysaccharides; 0303 health sciences; Membrane Glycoproteins; Hepatitis, Viral, Human; Liver Cirrhosis, Biliary; Cell Membrane; Lipopolysaccharide Receptors; NF-kappa B; Immunoglobulins; Peptidoglycan; Middle Aged; Flow Cytometry; Ligands; Monocytes; Toll-Like Receptor 2; 3. Good health; 03 medical and health sciences; Antigens, CD; Chronic Disease; Myeloid Differentiation Factor 88; Humans; RNA, Messenger; Aged

Toll-like receptors (TLRs) have emerged as a key component of the innate immune system that triggers antimicrobial responses. Altered monocyte responses to ligands for TLRs have been reported in patients with primary biliary cirrhosis (PBC), yet the precise mechanism remains unknown.We investigated in vitro responses to a TLR4 ligand, lipopolysaccharide (LPS), using peripheral blood mononuclear cells and monocytes from 25 patients with PBC, 10 patients with chronic viral hepatitis (CVH), and 20 healthy individuals.After stimulation with LPS, we found significantly higher amounts of IL-1beta, IL-6, and IL-8 production in PBC patients. Through the TLR4 signaling pathway, activation of NF-kappaB and expression of MyD88 mRNA were significantly increased in PBC patients, and the level of TLR4 expression was significantly increased on PBC monocytes as compared with CVH patients and controls. Of significance, the surface expression of RP105, which has recently been shown to be involved in negative regulation of TLR4 signaling, on PBC monocytes was significantly decreased in comparison with CVH patients (P=0.016) and controls (P<0.001).These results suggest that expression of RP105 and TLR4 is altered on PBC monocytes, which appear to be hypersensitive to LPS, resulting in increased secretion of pro-inflammatory cytokines.